Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years.
about
BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV.Assessment of vaccine candidates for persons aged 50 and older: a review.Shingles (herpes zoster) vaccine (zostavax(®)): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years.Zostavax : a subcutaneous vaccine for the prevention of herpes zoster.Systemic varicella zoster virus reactive effector memory T-cells impaired in the elderly and in kidney transplant recipients.
P2860
Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Immunogenicity and safety of Z ...... in individuals aged ≥50 years.
@ast
Immunogenicity and safety of Z ...... in individuals aged ≥50 years.
@en
type
label
Immunogenicity and safety of Z ...... in individuals aged ≥50 years.
@ast
Immunogenicity and safety of Z ...... in individuals aged ≥50 years.
@en
prefLabel
Immunogenicity and safety of Z ...... in individuals aged ≥50 years.
@ast
Immunogenicity and safety of Z ...... in individuals aged ≥50 years.
@en
P2093
P2860
P356
P1433
P1476
Immunogenicity and safety of Z ...... in individuals aged ≥50 years.
@en
P2093
Anne Fiquet
Christine Sadorge
Robert Arnou
Stéphane Thomas
P2860
P304
P356
10.4161/HV.7.10.16480
P577
2011-10-01T00:00:00Z